<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676284</url>
  </required_header>
  <id_info>
    <org_study_id>DURE04</org_study_id>
    <nct_id>NCT02676284</nct_id>
  </id_info>
  <brief_title>Durolane SJ for Treatment of Rhizarthrosis</brief_title>
  <official_title>Study of the Clinical and Biomechanical Effectiveness of Durolane SJ in Rhizarthrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zambon SAU</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bioventus LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zambon SAU</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a prospective, open, non-comparative study in 36 subjects with rhizarthrosis
      comparing signs and symptoms before and after a single injection of DUROLANE SJ in the
      affected hand. Subjects were assessed pre-treatment and at 1, 3, and 6 months post-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is associated with a post marketing commitment with the European Notified Body,
      BSI, to confirm DUROLANE SJ's effectiveness in rhizarthrosis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain as measured by the VAS scale</measure>
    <time_frame>over 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomechanical function scores as measured by the QuickDASH questionnaire</measure>
    <time_frame>over 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomechanical thumb opposition scores as measured by the Kapandji thumb opposition test</measure>
    <time_frame>over 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Rhizarthrosis</condition>
  <arm_group>
    <arm_group_label>Durolane SJ</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Durolane SJ</intervention_name>
    <description>single dose injection</description>
    <arm_group_label>Durolane SJ</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects of both sexes aged 18 to 75 years.

          -  Diagnosis of Grade II-III rhizarthrosis in either hand, according to the criteria of
             Eaton and Littler.

          -  TMC joint pain lasting longer than 6 months and baseline pain value greater than or
             equal to 4 on the VAS scale (0 to 10) and less than 4 in the contralateral hand joint
             if there is pain.

        Exclusion Criteria:

          -  Anticoagulant medication

          -  Rheumatic disease involving the wrist, hand and fingers, such as rheumatoid arthritis
             or gout

          -  Active rheumatoid arthritis

          -  Previous surgery of the hand

          -  Systemic infectious processes

          -  Neoplastic disease

          -  Subjects with contraindications to hyaluronic acid

          -  Subjects with known hypersensitivity to hyaluronic acid or any of the components of
             the preparation under study

          -  Previous hyaluronic acid injections in the hand

          -  Subjects likely to miss the clinical follow-up visits

          -  Taking of analgesics 24 hours before scheduled clinical assessments

          -  Pregnant subjects

          -  Any condition that in the opinion of the physician recommends exclusion of the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eloisa Velasco Ruiz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Sant Joan Despi Moises Broggi</affiliation>
  </overall_official>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>February 3, 2016</last_update_submitted>
  <last_update_submitted_qc>February 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

